1. Evaluation of the Trypanosoma brucei 6-oxopurine salvage pathway as a potential target for drug discovery
- Author
-
Eva Doleželová, Petr Špaček, Ondřej Gahura, Dianne T. Keough, David Terán, Dana Hocková, Luke W. Guddat, Alena Zíková, Zuzana Kotrbová, and Michaela Procházková
- Subjects
Models, Molecular ,0301 basic medicine ,Purine ,Hypoxanthine Phosphoribosyltransferase ,Biochemistry ,chemistry.chemical_compound ,RNA interference ,Catalytic Domain ,Drug Discovery ,Enzyme Inhibitors ,Nucleotide salvage ,Protozoans ,Crystallography ,biology ,Organic Compounds ,Nucleotides ,Drug discovery ,Physics ,lcsh:Public aspects of medicine ,Eukaryota ,Condensed Matter Physics ,Trypanocidal Agents ,3. Good health ,Nucleic acids ,Chemistry ,Infectious Diseases ,Genetic interference ,Physical Sciences ,Crystal Structure ,Phosphoribosyltransferase ,Epigenetics ,Metabolic Networks and Pathways ,Research Article ,Trypanosoma ,Guanine ,lcsh:Arctic medicine. Tropical medicine ,Purinones ,lcsh:RC955-962 ,Trypanosoma brucei brucei ,Trypanosoma brucei ,03 medical and health sciences ,Organophosphorus Compounds ,Trypanosoma Brucei ,Genetics ,Solid State Physics ,Humans ,Pentosyltransferases ,030102 biochemistry & molecular biology ,Organic Chemistry ,Organisms ,Chemical Compounds ,Public Health, Environmental and Occupational Health ,Biology and Life Sciences ,lcsh:RA1-1270 ,biology.organism_classification ,Parasitic Protozoans ,030104 developmental biology ,chemistry ,Purines ,Enzymology ,biology.protein ,RNA ,Gene expression ,Phosphonic Acids ,Nucleoside ,Trypanosoma Brucei Gambiense - Abstract
Due to toxicity and compliance issues and the emergence of resistance to current medications new drugs for the treatment of Human African Trypanosomiasis are needed. A potential approach to developing novel anti-trypanosomal drugs is by inhibition of the 6-oxopurine salvage pathways which synthesise the nucleoside monophosphates required for DNA/RNA production. This is in view of the fact that trypanosomes lack the machinery for de novo synthesis of the purine ring. To provide validation for this approach as a drug target, we have RNAi silenced the three 6-oxopurine phosphoribosyltransferase (PRTase) isoforms in the infectious stage of Trypanosoma brucei demonstrating that the combined activity of these enzymes is critical for the parasites’ viability. Furthermore, we have determined crystal structures of two of these isoforms in complex with several acyclic nucleoside phosphonates (ANPs), a class of compound previously shown to inhibit 6-oxopurine PRTases from several species including Plasmodium falciparum. The most potent of these compounds have Ki values as low as 60 nM, and IC50 values in cell based assays as low as 4 μM. This data provides a solid platform for further investigations into the use of this pathway as a target for anti-trypanosomal drug discovery., Author summary Human African Trypanosomiasis (HAT) is a life-threatening infectious disease caused by the protozoan parasite, Trypanosoma brucei. Current treatments suffer from low efficacy, toxicity issues and complex medication regimens. Moreover, an alarming number of these parasites are demonstrating resistance to current drugs. For these reasons, there is a renewed effort to develop new classes of modern therapeutics based upon the unique T. brucei cellular processes. One potential new drug target is 6-oxopurine phosphoribosyltransferase (PRTase), an enzyme central to the purine salvage pathway and whose activity is critical for the production of the nucleotides (GMP and IMP) required for DNA/RNA synthesis within this protozoan parasite. We demonstrated that T. brucei encodes two isoforms of hypoxanthine-guanine PRTases (HGPRT) and one hypoxanthine-guanine-xanthine PRTase (HGXPRT). The concurrent activity of these enzymes is required for the normal cell growth in vitro. Moreover, acyclic nucleoside phosphonates represent a promising class of potent and selective compounds as they inhibit the enzymes with Ki values in nanomolar range and exert cytotoxic effects on T. brucei cells grown in vitro with EC50 values in the single digit micromolar range. Our results provide a new foundation for further investigations of these compounds in vivo and suggest that 6-oxopurine salvage pathway represents a possible target for future drug discovery efforts directed at eliminating HAT.
- Published
- 2018